According to Baihua Pharmaceutical's announcement, the cumulative deviation value of the daily closing price increase of the company's stock exceeded 100% within 10 consecutive trading days, which is a serious abnormal fluctuation. In the first quarter of 2026, the company's revenue was 67.1829 million yuan, down 30.68% year on year, and net profit was 6.6427 million yuan, down 67.94% year on year. The stock price increase deviated seriously from the operation. Currently, the company's rolling price-earnings ratio is 203 times, far higher than 35.06 times that of the industry, and the turnover rate soared to 34.43% on August 12. The controlling shareholder has no major asset restructuring plans for the next 36 months, reminding investors to be aware of transaction risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.